Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FTC approves Whole Foods order

This article was originally published in The Tan Sheet

Executive Summary

Whole Foods Market will divest 13 operating and 19 closed locations as part of a final consent order issued May 28 by the Federal Trade Commission. The Austin, Texas-based premium grocery chain settled with the agency after FTC pursued an antitrust case against the firm's 2007 acquisition of competitor Wild Oats (1"The Tan Sheet" March 9, 2009, In Brief). The final order, which the four commissioners unanimously approved, says an appointed divestiture trustee will have six months to complete the divestiture

You may also be interested in...



Whole Foods settles

High-end grocery store chain Whole Foods Market will sell 32 of the stores it acquired when it bough its former competitor Wild Oats in 2007 and will divest related assets, according to a settlement with the Federal Trade Commission. The 1agreement resolves allegations the chain's acquisition of Wild Oats stores was anticompetitive, FTC announces March 6 (2"The Tan Sheet" Feb. 2, 2009, In Brief)

FDA To Ramp Up ASCA Pilot In 2021

A report from the US FDA says the agency will focus on updating its premarket submission portal, training staff and taking additional steps to start taking in applications for ASCA pilot participant sponsors.

Scotland's MGB Plots Phase III For Promising Antibacterial

With a late-stage compound on its hands, MGB is currently in discussions with several biotech and pharma companies and also with venture capitalists to continue late-stage development of a novel antibiotic which could transform treatment of Clostridium difficile.

UsernamePublicRestriction

Register

LL035386

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel